Affimed
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch Affimed and buy or sell other stocks, ETFs, and their options commission-free!About AFMDQ
Affimed NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of cancer immunotherapies. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs.
CEOShawn M. Leland
CEOShawn M. Leland
Employees78
Employees78
HeadquartersMannheim, Baden Wuerttemberg
HeadquartersMannheim, Baden Wuerttemberg
Founded2000
Founded2000
Employees78
Employees78
AFMDQ Key Statistics
Market cap1.52K
Market cap1.52K
Price-Earnings ratio—
Price-Earnings ratio—
Dividend yield—
Dividend yield—
Average volume2.77K
Average volume2.77K
High today$0.0001
High today$0.0001
Low today$0.0001
Low today$0.0001
Open price$0.0001
Open price$0.0001
Volume340.00
Volume340.00
52 Week high$0.05
52 Week high$0.05
52 Week low$0.00
52 Week low$0.00
Stock Snapshot
As of today, Affimed(AFMDQ) shares are valued at $0.00. The company's market cap stands at 1.52K.
During the trading session on 2026-07-25, Affimed(AFMDQ) shares reached a daily high of $0.00 and a low of $0.00. At a current price of $0.00, the stock is 0.0% higher than the low and still 0.0% under the high.
Trading volume for Affimed(AFMDQ) stock has reached 340, versus its average volume of 2.77K.
Over the past 52 weeks, Affimed(AFMDQ) stock has traded between a high of $0.05 and a low of $0.00.
Over the past 52 weeks, Affimed(AFMDQ) stock has traded between a high of $0.05 and a low of $0.00.
People also own
Based on the portfolios of people who own AFMDQ. This list is generated using Robinhood data, and it’s not a recommendation.